An OIT formulation containing peanut (200 μg) and CpG (1.8 μg) encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles that reduces allergic disease also decreases peanut-specific IgE and IgG1 and increases peanut-specific IgG2a (32), demonstrating a shift in serum antibody responses. This evidence concerns the gene IGHE and allergic disease.